Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?

David J. VanderWeele; Joshua J. Meeks; Maha Hussain

doi:10.21037/tau.2018.12.07

Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?

David J. VanderWeele, Joshua J. Meeks, Maha Hussain

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	S91-S92
Journal	Translational Andrology and Urology
Volume	8
DOIs	https://doi.org/10.21037/tau.2018.12.07
State	Published - 2019

ASJC Scopus subject areas

Urology
Reproductive Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21037/tau.2018.12.07

Cite this

@article{7d060ad66f924ce5853028352de07527,

title = "Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?",

author = "VanderWeele, {David J.} and Meeks, {Joshua J.} and Maha Hussain",

note = "Funding Information: The study was supported by Prostate Cancer Foundation, Hope Foundation, VHA, NIH, DoD.",

year = "2019",

doi = "10.21037/tau.2018.12.07",

language = "English (US)",

volume = "8",

pages = "S91--S92",

journal = "Translational Andrology and Urology",